However, more recent evidence has demonstrated that human PDAC tumors have a varying number of CD8+ T cells with considerable spatial heterogeneity within the tumor [125,126,127] and that some patients with PDAC actually harbor neoantigens that can drive potent T cell immunity [18,128,129], suggesting the existence of other undiscovered factors that drive resistance to ICB. Here, CD8A is linked to neoplasm.